fibin Antibody

What is FIBIN and what applications are FIBIN antibodies suitable for?

FIBIN (fin bud initiation factor homolog) is a 211 amino acid protein with a molecular weight of approximately 24 kDa. The gene encoding FIBIN is conserved across species, with the human FIBIN gene having the NCBI Gene ID 387758 and UniProt ID Q8TAL6 .

FIBIN antibodies are primarily used for:

• Immunohistochemistry on paraffin-embedded sections (IHC-P)

• Sandwich ELISA (sELISA)

• Functional studies (FuncS)

• Immunocytochemistry/immunofluorescence (ICC/IF)

These antibodies show confirmed reactivity with human samples, particularly in brain tissue, and require appropriate antigen retrieval methods for optimal results. For IHC applications, suggested dilution ranges from 1:50 to 1:500, though optimal concentration should be determined for each specific application .

What are the recommended storage and handling protocols for FIBIN antibodies?

For optimal stability and function of FIBIN antibodies:

When handling the antibody for experiments, it's recommended to:

• Thaw completely at room temperature before use

• Mix gently by inversion or pipetting (avoid vortexing which can denature the antibody)

• Return to -20°C promptly after use

• Use appropriate purification methods (e.g., antigen affinity purification) for isolation of specific antibody fractions when needed

How do I determine the optimal antibody concentration for my specific experiment?

Determining optimal antibody concentration requires systematic titration:

• Initial concentration range testing: Begin with the manufacturer's recommended dilution range (e.g., 1:50-1:500 for IHC applications) .

• Progressive optimization:

  • For immunohistochemistry: Test dilutions within this range on control tissues known to express FIBIN

  • For ELISA: Generate a standard curve using serial dilutions to identify the linear response range

  • For ICC/IF: Test multiple fixation protocols alongside antibody concentration optimization

• Signal-to-noise evaluation: Assess specific staining versus background noise at each concentration to determine the optimal dilution that provides maximum specific signal with minimal background.

• Controls integration:

  • Positive control: Known FIBIN-expressing tissue (e.g., human brain tissue)

  • Negative control: Tissue known not to express FIBIN

  • Secondary antibody-only control: To assess non-specific binding

The optimal antibody concentration will be sample-dependent and may require adjustment based on the specific experimental system used .

How can I validate the specificity of FIBIN antibody binding in complex tissue samples?

Validating antibody specificity requires multiple complementary approaches:

• Epitope competition assays: Pre-incubate the antibody with excess purified FIBIN fusion protein (such as Ag24265, which was used as immunogen) before application to the sample. Specific staining should be abolished.

• Knockdown/knockout validation:

  • Utilize FIBIN siRNA knockdown in cell culture models, comparing staining patterns before and after FIBIN reduction

  • Use CRISPR-Cas9 edited cell lines or tissue samples as negative controls

  • This approach is similar to the FN knockdown study demonstrated in related antibody research to validate binding specificity

• Orthogonal detection methods:

  • Compare protein detection with antibodies targeting different FIBIN epitopes

  • Correlate protein detection with mRNA expression using in situ hybridization or RT-PCR

  • Confirm specificity through mass spectrometry of immunoprecipitated proteins

• Cross-reactivity assessment:

  • Test the antibody against a panel of closely related proteins

  • For FIBIN antibody, particularly test against other proteins with similar structural domains to assess potential cross-reactivity

• Multiple application validation: Confirm specific binding across different applications (e.g., if the antibody works in both IHC and Western blot with consistent molecular weight detection)

What are the optimal antigen retrieval methods for FIBIN detection in FFPE tissue samples?

Antigen retrieval is critical for successful FIBIN detection in formalin-fixed paraffin-embedded (FFPE) tissues:

• Primary recommended method: TE buffer at pH 9.0

  • Heat-induced epitope retrieval (HIER) using pressure cooker or microwave

  • Typical incubation time: 15-20 minutes at high temperature followed by 20-minute cooling

• Alternative method: Citrate buffer at pH 6.0

  • May provide improved results in specific tissue types

  • Compare both methods in parallel on serial sections to determine optimal protocol

• Tissue-specific considerations:

  • For human brain tissue (known to express FIBIN), pH 9.0 buffer typically provides superior results

  • For tissues with high protease content, addition of protease inhibitors to retrieval solution may be beneficial

• Concentration-dependent parameters:

  • For paraffin sections, a concentration of 10 μg/ml FIBIN antibody is generally required

  • For frozen sections, lower concentrations (1-10 μg/ml) may be sufficient

• Validation approach:

  • Always include positive control tissues with known FIBIN expression

  • Run parallel negative controls (secondary antibody only)

  • Consider side-by-side comparison with other validated antibodies against FIBIN

How can I determine whether observed FIBIN staining patterns represent specific binding or potential artifacts?

Distinguishing specific FIBIN staining from artifacts requires systematic analysis:

• Pattern analysis:

  • True FIBIN staining should correlate with known subcellular localization patterns

  • Artifacts often present as:

    • Edge effects around tissue sections

    • Uniform staining across diverse tissue structures

    • Nuclear staining when the protein is known to be cytoplasmic or membrane-associated

• Control integration:

  • Include isotype controls (same species, same Ig class as primary antibody)

  • Secondary antibody-only controls

  • Known positive and negative tissue controls

• Absorption controls:

  • Pre-absorb antibody with recombinant FIBIN

  • Specific staining should be eliminated while non-specific binding may remain

• Multi-antibody validation:

  • Compare staining patterns using antibodies targeting different FIBIN epitopes

  • Consistent patterns across different antibodies suggest specificity

• Context-specific considerations:

  • In immunohistochemistry of normal pancreatic tissues, antibodies like clone 99 and clone 1101 (though for different targets) showed minimal non-specific binding, demonstrating proper control methodology

  • Evaluate whether staining intensity correlates with expected expression levels across different tissues

How can I optimize FIBIN antibody performance in Western blot applications?

Although FIBIN antibody (27051-1-AP) is primarily validated for IHC and ELISA applications , researchers may need to adapt it for Western blot analysis:

• Sample preparation optimization:

  • Use multiple protein extraction methods to ensure optimal FIBIN recovery

  • Include protease inhibitors to prevent degradation

  • Test both reducing and non-reducing conditions, as epitope accessibility may differ

• Blocking optimization:

  • Test different blocking reagents: 5% non-fat milk, 5% BSA, or commercial blocking buffers

  • Optimize blocking time (typically 1-2 hours at room temperature or overnight at 4°C)

• Antibody concentration titration:

  • Begin with 1:1000 dilution and adjust based on signal intensity

  • Extended incubation (overnight at 4°C) may improve sensitivity

• Detection system optimization:

  • Compare sensitivity of different secondary antibodies

  • For low abundance proteins, consider signal amplification systems

  • Test both chemiluminescent and fluorescent detection methods

• Troubleshooting approach for common issues:

What considerations should be taken when using FIBIN antibody across different species samples?

While the FIBIN antibody (27051-1-AP) is validated for human samples , researchers often need to extend applications to other species:

• Sequence homology analysis:

  • Perform sequence alignment of the immunogen region across target species

  • Higher homology suggests greater likelihood of cross-reactivity

  • FIBIN is a conserved protein, but species-specific variations may affect epitope recognition

• Experimental validation in non-human samples:

  • Always perform comprehensive validation when extending to new species

  • Include appropriate positive and negative controls from the target species

  • Consider the approach used in antibody 102-10 research, where conservation across mouse and human was methodically verified

• Species-specific protocol modifications:

  • Optimize fixation protocols for each species' tissues

  • Adjust antigen retrieval conditions based on tissue characteristics

  • Consider species-specific secondary antibody selection to minimize background

• Comparative analysis approach:

  • When possible, run parallel experiments with samples from validated species

  • Correlate staining patterns with known expression data from multiple species

  • Consider orthogonal validation methods (RT-PCR, protein expression data) in the target species

What kinetic binding properties should be considered when comparing different FIBIN antibody clones?

When evaluating different antibody clones for FIBIN detection, binding kinetics represent critical selection criteria:

• Clone selection considerations beyond kinetics:

  • Production yield and stability (e.g., clone 1101 demonstrated superior hybridoma production and long-term stability compared to clone 99 in related antibody research)

  • Non-specific binding profile across diverse tissues

  • Performance consistency across different application methods

How should I interpret FIBIN expression patterns in relation to disease pathology?

Interpreting FIBIN expression in pathological contexts requires systematic analysis:

• Quantitative assessment approaches:

  • Develop clear scoring criteria (e.g., percentage of positive cells, staining intensity)

  • Consider digital image analysis for objective quantification

  • Use standardized reporting formats to enable cross-study comparisons

• Contextual tissue evaluation:

  • Compare FIBIN expression in diseased tissue to matched normal controls

  • Assess both cellular distribution and subcellular localization changes

  • Correlate with other molecular markers to establish pattern associations

• Multiple detection methodology integration:

  • Validate IHC findings with complementary methods (Western blot, RT-PCR)

  • Consider multiplexed staining to assess FIBIN in relation to other markers

  • This multi-method approach parallels techniques used in related antibody research where immunohistochemistry findings were correlated with ELISA results

• Clinical correlation considerations:

  • Establish relationships between expression patterns and clinical parameters

  • Assess potential prognostic or diagnostic significance through proper statistical analysis

  • Validate findings in independent patient cohorts when possible

• Mechanistic interpretation frameworks:

  • Consider known FIBIN biological functions when interpreting pathological changes

  • Evaluate whether expression changes represent causal factors or response mechanisms

  • Develop hypotheses for functional significance that can be tested experimentally

What are the most effective experimental designs for studying FIBIN's role in cellular functions?

Designing robust experiments to investigate FIBIN's cellular functions requires strategic planning:

• Loss-of-function approaches:

  • siRNA or shRNA knockdown: Transient reduction to assess acute effects

  • CRISPR-Cas9 knockout: Complete elimination for long-term functional studies

  • Dominant-negative mutants: To disrupt specific protein interactions or functions

• Gain-of-function strategies:

  • Controlled overexpression systems (inducible promoters)

  • Tagged FIBIN constructs for localization and interaction studies

  • Domain-specific mutants to investigate structure-function relationships

• Functional readout selection:

  • Cell proliferation and viability assays

  • Migration and invasion assays (particularly relevant if FIBIN influences matrix interactions)

  • Differentiation markers in developmental contexts

  • Signaling pathway activation markers

• Interaction studies:

  • Co-immunoprecipitation with FIBIN antibodies to identify binding partners

  • Proximity ligation assays for in situ interaction visualization

  • Pull-down assays with recombinant FIBIN

  • This approach parallels methods used to identify binding partners in related research, such as the fibronectin binding study with FFE antibody

• Temporal dynamics assessment:

  • Time-course experiments following perturbation

  • Live-cell imaging with fluorescently tagged FIBIN

  • Inducible expression/knockout systems to control timing of functional changes

How can I develop a quantitative ELISA assay for FIBIN using available antibodies?

Developing a reliable quantitative ELISA for FIBIN requires methodical optimization:

• Assay format selection:

  • Sandwich ELISA: Requires two antibodies recognizing different FIBIN epitopes

  • Competitive ELISA: Useful when only one antibody is available

  • Direct ELISA: Simplest design but potentially less specific

• Antibody pair optimization for sandwich ELISA:

  • Test the FIBIN antibody (27051-1-AP) as either capture or detection antibody

  • Identify a complementary antibody targeting a different FIBIN epitope

  • Evaluate different combinations for optimal sensitivity and specificity

• Standard curve development:

  • Use recombinant FIBIN protein at known concentrations

  • Create a multi-point standard curve (typically 7-8 points with 2-fold dilutions)

  • Ensure curve covers expected physiological concentration range

• Protocol optimization parameters:

• Validation requirements:

  • Determine limit of detection (LOD) and quantification (LOQ)

  • Assess intra- and inter-assay variation (CV%)

  • Spike recovery tests to evaluate matrix effects

  • Parallelism assessment between recombinant and native FIBIN

What approaches can be used to investigate the relationship between FIBIN and other tissue proteins?

Investigating FIBIN's relationship with other proteins requires multi-faceted approaches:

• Co-localization analysis:

  • Dual immunofluorescence staining with FIBIN antibody and antibodies against potential interacting proteins

  • Confocal microscopy for high-resolution spatial relationship assessment

  • Quantitative co-localization metrics (Pearson's correlation, Manders' coefficients)

• Protein-protein interaction studies:

  • Co-immunoprecipitation using FIBIN antibody

  • Proximity ligation assay (PLA) for in situ detection of protein interactions

  • FRET/BRET assays for dynamic interaction monitoring

  • This strategic approach is supported by research methods used to identify the relationship between antibody binding and matrix proteins in related studies

• Functional relationship assessment:

  • Knockdown/overexpression of FIBIN combined with monitoring of related protein levels

  • Pathway inhibition studies to place FIBIN in signaling networks

  • Rescue experiments to confirm functional dependencies

• Methodological considerations for challenging protein relationships:

  • For transient or weak interactions: Use chemical crosslinking before immunoprecipitation

  • For membrane-associated interactions: Consider specialized extraction conditions

  • For context-dependent interactions: Examine under different physiological conditions (stress, differentiation, etc.)

• Advanced techniques for comprehensive interaction mapping:

  • Mass spectrometry-based interactome analysis

  • Yeast two-hybrid screening

  • BioID or APEX proximity labeling